

Remarks

Claims 57-62, 64-77, 79-83, and 87-89 are pending in the subject application. By this Amendment, Applicants have amended claims 57, 58, 68-73, and 87-89. Support for the amendments can be found throughout the subject specification and in the claims as originally filed (see, for example, the summary of the invention). Entry and consideration of the amendments presented herein is respectfully requested. Accordingly, claims 57-62, 64-77, 79-83, and 87-89 are currently before the Examiner. Favorable consideration of the pending claims is respectfully requested.


At the outset, Applicants wish to thank Examiner Mertz for contacting the undersigned to discuss claim amendments for placing this matter in condition for allowance on December 11, 2007. In this teleconference, Examiner Mertz suggested amendments to the claims such that this application could be allowed and requested the filing of this second supplemental amendment in view of the number of instances the suggested phrase appears in the instant claim set. Accordingly, this supplemental amendment is being filed pursuant to that teleconference and provides for the insertion of the phrase "an activity of" within various claims. Additionally, it was suggested that the claims 87-89 be amended to indicate that the activity was the recruitment of leukocytes. It is the understanding of the undersigned that this supplemental amendment, in conjunction with the previously filed response, appears to place this application in condition for allowance and such action is respectfully requested.

It should be understood that the amendments presented herein have been made solely to expedite prosecution of the subject application to completion and should not be construed as an indication of Applicants' agreement with or acquiescence in the Examiner's position. Applicants expressly reserve the right to pursue the invention(s) disclosed in the subject application, including any subject matter canceled or not pursued during prosecution of the subject application, in a related application.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Applicants invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/sl